Bile Duct Cancer Market Size

Global Bile Duct Cancer Market size was valued at USD 3.6 billion in 2023 and is poised to grow from USD 3.91 billion in 2024 to USD 7.5 billion by 2032, growing at a CAGR of 8.5% during the forecast period (2025-2032).

The increasing prevalence of bile duct cancer (cholangiocarcinoma), advancement in technology, rise in research and development activities drives the growth of the market. According to Cancer research institute, around 8,000 people in the United State are diagnosed with bile duct cancer each year. The incidence rate of bile duct cancer gradually increases, across the globe, mostly in aging population and region with high incidence of liver fluke infection, hepatitis C and hepatitis B.

In addition, advancement in technology propel the growth of the market. Diagnostic imaging technologies such as PET-CT and MRI helps in early detection of patient which enhance patient treatment planning and recovery. The Memorial Sloan Kettering Cancer center use the advanced imaging technology such as triphasic CT scans, magnetic resonance cholangiopancreatography, positron emission tomography & ultrasound, for diagnosis of bile duct tumor.

The rise in awareness about bile duct cancer among population propel the growth of the market. THE Alan Morement Memorial Fund (AMMF) create awareness of cholangiocarcinoma (bile duct cancer), supplying information to those who need it, and raising funds to support specialised research teams in their work into the causes, methods of earlier diagnosis and treatments of this disease.

Furthermore, The increasing investment in research and development activities for the development of advanced treatment and diagnostic option are accelerating innovations in this section. The research on bile duct cancer is taking place in medical centers, many university hospitals and other institute across the globe. Each year, the scientist come up with more analysis on cause of disease, its prevention and treatment of disease. Furthermore

However, limited availability of effective late-stage therapies, the high cost of treatment, and the complex nature of early diagnosis act as a major restraint, mostly in low and middle income countries.

How is AI Advancing Diagnosis and Treatment of Cholangiocarcinoma?

Cholangiocarcinoma lacks accurate early diagnosis methods. Thus, many researchers are currently focusing on applying AI to the early diagnosis of cholangiocarcinoma by the use of different clinical information of the patient. The AI is also used in advanced treatment planning and drug discovery mechanism. AI-powered imaging tools are used to detect bile duct cancer at an early stage through pattern recognition in MRI, CT, and PET scans. These tools help the physician/radiologist to identify small abnormalities which remain unnoticed through general analysis.

Technology such as deep learning (DL), and machine learning (ML) including support vector machines (SVMs), logistic regression, convolutional neural networks (CNNs), and artificial neural networks (ANNs), enhance early detection, accuracy, and clinical decision-making through data integration and advanced pattern recognition.

In addition, the ongoing R&D activities on AI implementation in bile duct cancer treatment surge the growth of the market. According to a journal of the American Association for Cancer Research (AACR), in 2024, Lunit announced that the AI biomarker, is utilize in one of the studies to predict the treatment response in bile duct cancer patient.